A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments

This study is testing belantamab mafodotin — an antibody-drug that targets a protein on multiple myeloma cells — both alone and in combination with other treatments, for patients whose multiple myeloma has returned or stopped responding to previous therapies. **You may be eligible if...** - You are 18 or older with a confirmed diagnosis of multiple myeloma - Your cancer has relapsed or progressed after previous treatment - You have received at least 3 prior lines of treatment (including lenalidomide, a proteasome inhibitor, and an anti-CD38 antibody) for most study parts; or at least 1 prior treatment for part 3 - Your disease is measurable by blood or urine tests - You are in generally good health (ECOG performance status 0–2) - If you previously had a stem cell transplant, it was at least 100 days ago with no active infection **You may NOT be eligible if...** - Your myeloma is clinically unstable or progressing very rapidly - You have significant organ damage (heart, kidney, liver) beyond the study's acceptable limits - You have an active serious infection - You are pregnant or breastfeeding - You have previously had a severe reaction to belantamab or similar drugs Talk to your doctor to see if this trial is right for you.